UK Government's AI Growth Lab: Fast-Tracking AI Adoption Through Regulatory Sandboxes
UK Government Launches AI Growth Lab: Regulatory Sandboxes to Fast-Track Innovation in Healthcare, Housing, and Professional Services
21 October: Technology Secretary Liz Kendall has announced plans for an AI Growth Lab, regulatory sandboxes where companies can test AI products in real-world conditions with certain rules temporarily relaxed under strict supervision. Initially targeting healthcare, professional services, transport, and advanced manufacturing robotics, the sandboxes aim to accelerate responsible AI deployment while cutting bureaucracy that "can choke innovation."
The announcement comes alongside the Chancellor's Regional Investment Summit, where reforms aim to save businesses nearly £6 billion annually by 2029 by reducing pointless admin tasks. Currently, only 21% of UK firms use AI, but the OECD estimates AI could improve UK productivity by 1.3 percentage points yearly, worth £140 billion equivalent.
Real-world applications could include AI tools helping health workers deliver better patient care on accelerated timelines, reducing NHS waiting lists and time demands on frontline staff.
In housing, typical development applications currently rack up 4,000 pages of documentation and take 18 months from submission to approval. AI could slash those times, supporting the government's plan to build 1.5 million new homes by end of Parliament.
The sandboxes won't allow regulations to be "switched on or off at will" but will see time-limited restrictions on specific regulatory hurdles under close supervision by tech and regulatory experts.
Strong safeguards include strict licensing schemes, with breaches stopping testing immediately and opening users to potential fines. Exclusions include consumer protection, safety provisions, fundamental rights, workers' protections and intellectual property rights.
A separate £1 million pot will support the Medicines and Healthcare products Regulatory Agency (MHRA) to pilot AI-assisted tools for drug discovery and clinical trial assessments, keeping all decisions "firmly in human hands."
The government is launching a public call for views on whether the programme should be run in-house or overseen by regulators themselves.
We want your views:
- Will regulatory sandboxes genuinely accelerate innovation, or create two-tier systems where only well-resourced companies can participate?
- How do we ensure "strict supervision" and "strong safeguards" actually protect public interest rather than becoming tick-box exercises?
- If AI can slash housing approval times, why aren't we questioning why those approvals require 4,000 pages in the first place?
- What happens when sandbox-tested AI products scale to full deployment - do the relaxed regulations snap back, or does this become permanent regulatory erosion?
- How will the £1 million MHRA pilot ensure AI-assisted drug discovery maintains rigorous safety standards while speeding approvals?
- Should worker protections and fundamental rights really be excluded from sandboxes, or does that risk creating blind spots in how AI affects people?
- Is 21% UK business AI adoption low because of regulatory barriers, or because most AI tools don't deliver the promised value?




